Trial Profile
Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 07 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.
- 07 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Dec 2022.
- 18 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Sep 2022.